Compare Colgate-Palmolive Company (CL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Crispr Therapeutics AG — how do they compare? Colgate-Palmolive Company trades at $92.31 (market cap $73.59B), while Crispr Therapeutics AG trades at $54.07 (market cap $5.23B). The key difference: Colgate-Palmolive Company is far larger — about 14.1× Crispr Therapeutics AG's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CL | CRSP | |
|---|---|---|
Market Cap | $73.59B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $76.78 |
52-Week Low | $74.98 | $44.34 |
Enterprise Value | $80.07B | $3.65B |
Dividend Yield | 2.3% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
